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Abstract 
Purpose: To investigate the effect of Radix bupleuri extract (RBE) on hyperplasia of mammary gland 
(HMG) in rats.  
Methods: Forty virgin female Wistar rats were randomly divided into control, HMG model, positive 
control (Rupisanjie capsule, RPSJC), and low-, middle-, and high-dose RBE groups. Estrogen and 
progestogen were intramuscularly injected into the rats to induce HMG. RPSJC and RBE were 
administered by intragastric administration. Changes in nipple height were measured; serum estradiol 
(E2), progesterone (P), prolactin (PRL), follicle-stimulating hormone (FSH), and luteinizing hormone 
(LH) levels were evaluated; and uterus and ovary indices were calculated. Morphological changes in 
mammary glands were observed by light microscopy.  
Results: Compared with HMG model rats, those treated with RBE had significantly decreased nipple 
height and uterus index (both p < 0.01), and the numbers of mammary gland lobules and secretion were 
reduced by RBE. The treatment also significantly decreased serum E2, PRL, and FSH levels (all p < 
0.01), while serum P and LH levels (p < 0.01) were significantly increased in RBE-treated HMG rats. 
Histopathologic observation confirmed that high dose of RBE attenuated HMG. 
Conclusion: The findings suggest that RBE has significant effect of anti-hyperplasia of mammary 
gland. 
 
Keywords: Radix Bupleuri, Anti-inflammatory, Anti-hyperplasia, Mammary gland, Nipple height, Uterus 
index 
 
Tropical Journal  of Pharmaceutical Research is indexed by Science Citation Index (SciSearch), Scopus, 
International Pharmaceutical Abstract, Chemical Abstracts, Embase, Index Copernicus, EBSCO, African 
Index Medicus, JournalSeek, Journal Citation Reports/Science Edition, Directory of Open Access Journals 




Hyperplasia of mammary gland (HMG) is a 
pathologic hyperplasia of the mammary gland 
lobules induced by an imbalance of estrogen and 
progesterone [1]. It is related to menstrual cycle, 
lactation, occupation, sex hormone use, diet, and 
stress [2,3]. The prevalence of HMG has 
increased in recent years, which is notable since 
it is associated with cancer. Indeed, HMG may 
be confused with early breast cancer. A recent 
study reported that traditional Chinese medicine 
(TCM) can significantly attenuate endocrine 
dyscrasia and inhibit HMG development [4]. 
Radix bupleuri, also named Chaihu in Chinese, is 
a common TCM herbal drug used to regulate 
endocrine disorders [5].  
 
In this study, we evaluated the effects of Radix 






Three batches of Radix bupleuri were collected    
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from Bozhou City, Anhui Province of China in 
July 2014. Taxonomic identification was 
performed by Professor Gan Gu of Zhejiang 
Pharmaceutical College, China. A voucher 
specimen of herbarium (No. RBE 201405031) 
was deposited in the College of Pharmacy, 
Zhejiang Pharmaceutical College, China for 
future reference. Aqueous RBE was obtained by 
steeping the dried plant three times in water at 
60 °C for 1 h each time before drying in an oven 
and freeze-drying the last extract obtained. The 
yield was 66.67 %; 1 g powder was roughly 




Virgin female Wistar rats weighing 200–240 g 
and Kunming female mice (18–22 g) were 
provided by the Heilongjiang University of 
Traditional Chinese Medicine (certificate No. 
SYXK 2006-0004). The animals had free access 
to feed and water and were allowed to 
acclimatize for at least 1 week before the study. 
The animal experiment was approved by Animal 
Care and Use Committee of Heilongjiang 
University of Traditional Chinese Medicine 
(approval ref no. 20120907) and was carried out 
in compliance with the Directive 2010/63/EU on 





Rats were treated with estrogen (0.5 mg/kg) 
intramuscularly for 25 days, followed by 
progestogen (5 mg/kg) for another 5 days to 
induce HMG. The rats were randomly divided 
into 6 groups of 10 rats each: control (untreated); 
HMG; HMG + positive control (RPSJC 800 
mg/kg); and three HMG + RBE groups (200, 400, 
or 800 mg/kg doses). From the 31st day, rats in 
the control and HMG groups received distilled 
water by gavage, those in the RPSJC group 
were treated with RPSJC, and the RBE groups 
received RBE. Treatments were given orally 
once daily for 4 weeks. 
 
Cotton pellet-induced granuloma test 
 
Sterile cotton pellets (10 mg) were 
subcutaneously implanted in the groin of 
anesthetized mice (18–22 g). Ten animals were 
used for every treatment. The animals received 
200, 400, or 800 mg/kg of RBE; RPSJC (800 
mg/kg); or saline (10 ml/kg). These treatments 
were given once a day through an oral cannula 
over 7 consecutive days. On the 8th day, the 
mice were sacrificed, and the cotton pellet 
removed, dried overnight at 60 °C, and weighed. 
The increase in weight was determined and used 




The nipple heights of all rats were measured 
after the treatment. Levels of serum estradiol 
(E2), progesterone (P), prolactin (PRL), follicle-
stimulating hormone (FSH), and luteinizing 
hormone (LH) were determined using enzyme-
linked immunosorbent assay kits (Shenzhen Xin-
Bo-Sheng Biological Technology Co Ltd, China). 
The uterus and ovary indices were calculated as 




Mammary gland tissues from each group were 
fixed in 10 % buffered formalin, embedded in 
paraffin, cut into 4-µm-thick sections, stained 
with hematoxylin-eosin (H-E) and Masson’s 
trichrome (M-T) and examined under a light 
microscope. HMG severity was based on four 
parameters (gland alveolus hyperplasia, lobules, 




Values are expressed as mean ± SEM. Multiple 
group comparisons were performed using one-
way analysis of variance (ANOVA) followed by 
Dunnett’s test to detect differences. P < 0.05 was 




Cotton pellet-induced granuloma 
 
RBE significantly and dose-dependently 
decreased the dried weight of the cotton pellet 
granuloma. The inhibitory values for 200, 400, 
and 800 mg/kg of RBE were 17.69, 21.82, and 
27.38 %, respectively. Notably, RPSJC had a 
lower inhibitory effect than the 200 mg/kg RBE 
dose. These results suggest that RBE effectively 
suppressed granulomatous tissue formation 
during chronic inflammation (Table 1). 
 
Effect of RBE on nipple height in rats 
 
As shown in Table 2, rat nipple height was 
significantly decreased by both RPSJC (800 
mg/kg) and RBE (800 mg/kg) compared with the 
HMG group (p < 0.01) (Table 2). 
 
Effect of RBE on serum sex hormone levels 
in rats 
 
After injection of estrogen and progestogen in  
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HMG model rats, E2, PRL, and FSH levels 
significantly increased, while P and LH levels 
decreased. RBE (800 mg/kg) treatment 
significantly decreased E2 PRL, and FSH 
compared with the HMG group (all p < 0.01), 
while it significantly increased P and LH levels (p 
< 0.01) (Table 3). 
 
Effect of RBE on uterus and ovary index in 
rats 
 
The uterus index of HMG rats was significantly 
increased compared with untreated control 
animals (p < 0.01). This was significantly 
attenuated by both RPSJC (p < 0.01) and high-
dose RBE (p < 0.05). The ovary index in the 
high-dose RBE group was not significantly 
different compared with untreated control 
animals (Table 4). 
Effect of RBE on mammary gland 
morphology 
 
Control rats did not have any evidence of 
histologic abnormalities or proliferative lesions; 
they also had fewer acinars and no mammary 
duct secretion (Fig 1A and B). Conversely, HMG 
rats exhibited intense hyperplasia of the gland 
alveolus and lobule, secretion, vessel 
arborization, lymphoplasia, and plasma cells (Fig 
1C and D). At week 4, RPSJC-treated group rats 
showed significantly decreased hyperplasia, less 
secretion, and fewer lymphocytes (Fig. 1E and 
F). RBE-H (800 mg/kg) markedly alleviated the 
degree of HMG by limiting hyperplasia in the 
gland alveolus and lobules and decreasing 
secretion and lymphocytes (Fig 1G and H). 
 
 
Table 1:  Effect of RBE on cotton pellet-induced inflammation in mice 
 
Groups Dosage (mg/kg) Granuloma weight (mg) Inhibition rate (%) P 
Control — 73.92 ± 9.45   
RPSJC 800 61.50 ± 11.75 16.8 >0.05 
RBE-L 200 60.84 ± 18.48 17.69 >0.05 
RBE-M 400 57.79 ± 13.24 21.82 <0.05 
RBE-H 800 53.68 ± 12.94 27.38 <0.05 
RBE-L: low-dose of RBE; RBE-M: middle-dose of RBE; RBE-H: high-dose RBE; RPSJC: 
Rupisanjie capsule; *p < 0.05, **p < 0.01 vs. model group 
 
Table 2: Nipple height in rats 
 
Group Dosage (mg/kg) Nipple height (mm) 
    Right 2 Right 3 
Control — 1.56 ± 0.15** 1.62 ± 0.21** 
Model — 2.98 ± 0.27 2.58 ± 0.29 
RPSJC 800 2.06 ± 0.24** 2.09 ± 0.09** 
RBE-H 800 1.72 ± 0.08** 2.06 ± 0.08** 
 RBE-H: high-dose RBE; RPSJC: Rupisanjie capsule; *p < 0.05 and **p < 0.01 
vs. model group 
 
Table 3: Effect of RBE on serum sex hormone levels in rats 
 
Group Dosage E2 (pmol/L) P (ng/mL) PRL (pg/mL) FSH (IU/L) LH (mIU/mL) 
Control — 2.80 ± 0.34** 1.41 ± 0.16** 286.37 ± 7.08** 0.08 ± 0.02*  1.85 ± 0.10* 
Model — 4.85 ± 0.19 0.63 ± 0.06 411.26 ± 8.91 0.52 ± 0.01 1.08 ± 0.05 
RPSJC 800 3.12 ± 0.28* 1.12 ± 0.20* 414.29 ± 15.24  0.48 ± 0.27 1.48 ± 0.10* 
RBE-H 800 2.67 ± 0.16** 1.23 ± 0.12** 278.93 ± 8.42** 0.12 ± 0.02** 1.77 ± 0.09* 
E2: estradiol; FSH: follicle-stimulating hormone; LH: luteinizing hormone; P: progesterone; PRL: prolactin; RBE-
H: high-dose RBE; RPSJC: Rupisanjie capsule; *p < 0.05, **p < 0.01 vs. model group 
 
Table 4: Effects of RBE on uterus and ovary index in rats 
 
Group Dosage Uterus index (mg/g) Ovary index (mg/g) 
Control — 2.13 ± 0.41** 0.68 ± 0.07 
Model — 2.87 ± 0.51 0.56 ± 0.14 
RPSJC 800 2.15 ± 0.22** 0.48 ± 0.07 
RBE-H 800 2.28 ± 0.46* 0.49 ± 0.08 
RBE-H: high-dose RBE; RPSJC: Rupisanjie capsule; *p < 0.05, **p < 0.01 vs. 
model group 
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Figure 1: Histologic images of mammary gland tissues. A-B, Control rats; C-D, HMG rats; E-F, HMG + RPSJC; 
G-H, RBE-H (800mg/kg). The left and right columns show ×100 and ×200 magnification, respectively. HY: 




There is evidence that chronic inflammation 
induced by persistent chemical, bacterial, or viral 
agents is a risk factor for cancer [7-10]. 
Inflammation is an important process required to 
fight microbial infections, heal wounds, and 
maintain tissue homeostasis, but it can also lead 
to cancer [11-13]. Several recent studies 
suggested that inflammation has an important 
role in all phases of tumor development, 
including tumor initiation, tumor promotion, 
invasion, metastatic dissemination, and immune 
system evasion [14]. Specifically, the 
development of breast cancer is related to 
inflammation. Epidemiological studies have 
revealed that non-steroidal anti-inflammatory 
drug use can decrease the risk of developing 
breast cancer [15,16].  
 
The inflammatory granuloma is a characteristic 
feature of chronic inflammatory processes. Dried 
weight of pellets correlates with the amount of 
granulomatous tissue; therefore, the results of 
the present study show that RBE-H exerts strong 
anti-inflammatory activity in a mouse model of 
chronic inflammation. 
 
In the present study, RBE effectively inhibited 
chronic proliferative inflammatory processes and 
in a rat model of HMG. The mechanism might 
involve regulating endocrine and immune 
functions to balance hormone levels and 





RBE is a potentially useful treatment for HMG. 
Therefore, further studies are required to develop 
Radix bupleuri for clinical use. 
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